OBJECTIVES Primary~Overall survival~Tumor response using RECIST criteria~Secondary~Determine the toxicity of the proposed treatment in this patient population.~Progression free survival~Locoregional control~Distant failure~STUDY DESIGN~Description of the Study Phase II study to evaluate the toxicity and overall survival of pulsed paclitaxel with concurrent thoracic radiotherapy, and adjuvant gemcitabine and carboplatin in stage IIIA and IIIB non-small cell lung cancer.~Rationale for Study Design The proposed doses of gemcitabine, carboplatin, paclitaxel, and thoracic radiation therapy have been previously studied and deemed safe. The design of this study is not to find the maximum tolerated dose (MTD) of these agents, but to study the toxicity and overall survival from this combination.~Outcome Measures Primary Outcome Measures~Overall survival~Tumor response using RECIST criteria~Secondary Outcome Measures~Locoregional control~Distant Failure~Progression free survival
This is a phase II study to evaluate the toxicity and overall survival of pulsed paclitaxel with concurrent thoracic radiotherapy, and adjuvant gemcitabine and carboplatin in stage IIIA and IIIB non-small cell lung cancer